Project Description
Ruxolitinib
Mechanism of action:
Janus kinase (JAK1 & JAK2) inhibitor
Indications:
Intermediate or high-risk myelofibrosis
Chemical Name:
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl) pyrazol-1-yl]propane nitrile
